Dominic Behan, Ph.D., Co-Founder and Chief Scientific Officer of Arena Pharmaceuticals, Inc. presides over the opening bell.

Wednesday September 12, 2007
from Nasdaq MarketSite
in New York's Times Square

Arena Pharmaceuticals, Inc.
[ARNA]

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced product candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for the treatment of obesity. Arena's broad pipeline of novel compounds targeting G protein-coupled receptors, an important class of validated drug targets, includes compounds being evaluated independently and with its partners, Merck & Co., Inc. and Ortho-McNeil Pharmaceutical, Inc.

Arena Pharmaceuticals(r) and Arena(r) are registered service marks of the company. "APD" is an abbreviation for Arena Pharmaceuticals Development.

Reprints

Click for larger pictures of the NASDAQ MarketSite. Additional Photographs for 09/12/2007 Download Hi-Res Quality Photo of this NASDAQ Market Open - Pictured: Dominic Behan, Ph.D., Co-Founder and Chief Scientific Officer of Arena Pharmaceuticals, Inc. presides over the opening bell. Organizations interested in obtaining NASDAQ-listed company bell ringing ceremony photographs for press purposes, must first receive approval from the listed company before requesting photographs from NASDAQ. Please provide the company contact information from whom you received approval to Jolene Libretto at Jolene.Libretto@nasdaq.com. Kindly credit © 2007, The Nasdaq Stock Market, Inc. Reprinted with permission. © Copyright 2007, The NASDAQ Stock Market, Inc. Reprinted with the permission of The Nasdaq Stock Market, Inc.